oliceridine (Olinvyk)

FDA-approved August 2020 Indications: - moderate to severe acute pain in adults - indicated for short-term IV use in hospitals or outpatient procedures Contraindications: - not for at-home use Dosage: - intravenous administration - maximum recommended daily dose 27 mg. Pharmacokinetics: - inactive metabolite Adverse effects: - less risk of respiratory depression & gastrointestinal dysfunction than morphine - QT prolongation at higher doses * boxed warning: - addiction, abuse & misuse - life-threatening respiratory depression - neonatal opioid withdrawal syndrome - risks from concomitant use with benzodiazepines or other CNS depressants Drug interactions: - benzodiazepines Mechanism of action: - G protein-selective agonist that targets the mu opioid receptor

References

George J Novel Opioid Gets FDA Nod - V oliceridine approved for hospital, controlled clinical settings. MedPage Today August 9, 2020 https://www.medpagetoday.com/neurology/opioids/87974